MAGENTA THERAPEUTICS INC (MGTA) Stock Price & Overview
NASDAQ:MGTA • US55910K1088
Current stock price
The current stock price of MGTA is 0.6996 USD. Today MGTA is down by -7.74%. In the past month the price decreased by -13.09%. In the past year, price decreased by -58.36%.
MGTA Key Statistics
- Market Cap
- 2.652M
- P/E
- N/A
- Fwd P/E
- 34.29
- EPS (TTM)
- -1.14
- Dividend Yield
- N/A
MGTA Stock Performance
MGTA Stock Chart
MGTA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to MGTA. When comparing the yearly performance of all stocks, MGTA is a bad performer in the overall market: 84.18% of all stocks are doing better.
MGTA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MGTA. No worries on liquidiy or solvency for MGTA as it has an excellent financial health rating, but there are worries on the profitability.
MGTA Earnings
MGTA Forecast & Estimates
6 analysts have analysed MGTA and the average price target is 1.02 USD. This implies a price increase of 45.8% is expected in the next year compared to the current price of 0.6996.
MGTA Groups
Sector & Classification
MGTA Financial Highlights
Over the last trailing twelve months MGTA reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 12.98% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
MGTA Ownership
MGTA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.29 | 369.653B | ||
| AMGN | AMGEN INC | 15.47 | 188.346B | ||
| GILD | GILEAD SCIENCES INC | 15.63 | 171.971B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 110.812B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 78.867B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.39 | 42.456B | ||
| INSM | INSMED INC | N/A | 30.821B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.581B | ||
| NTRA | NATERA INC | N/A | 27.795B | ||
| BIIB | BIOGEN INC | 10.97 | 25.833B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.73 | 25.444B | ||
| MRNA | MODERNA INC | N/A | 21.686B | ||
| INCY | INCYTE CORP | 12.46 | 18.97B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MGTA
Company Profile
Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Company Info
IPO: 2018-06-21
MAGENTA THERAPEUTICS INC
100 Technology Sq Fl 5
Cambridge MASSACHUSETTS 02139 US
CEO: Jason Gardner
Employees: 67
Phone: 18572012700.0
MAGENTA THERAPEUTICS INC / MGTA FAQ
Can you describe the business of MAGENTA THERAPEUTICS INC?
Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. The company is headquartered in Cambridge, Massachusetts and currently employs 67 full-time employees. The company went IPO on 2018-06-21. The firm is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. The company is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
What is the current price of MGTA stock?
The current stock price of MGTA is 0.6996 USD. The price decreased by -7.74% in the last trading session.
Does MAGENTA THERAPEUTICS INC pay dividends?
MGTA does not pay a dividend.
How is the ChartMill rating for MAGENTA THERAPEUTICS INC?
MGTA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is MGTA stock listed?
MGTA stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for MGTA stock?
MAGENTA THERAPEUTICS INC (MGTA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).